Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722678 | 0.87 | ACHE (0.82) | ACHECA12CA1CA2CA7 | |
| SCHEMBL747025 | 0.84 | GRM5 (0.56) | ACHEHPGDALDH1A1GRM5L3MBTL3 | |
| SCHEMBL1921224 | 0.83 | ALDH1A1 (0.56) | HPGDALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL27842179 | 0.83 | L3MBTL3 (0.47) | ACHECA12CA1CA2CA7 | |
| SCHEMBL436168 | 0.82 | ACHE (1.00) | ACHECA12CA1CA2CA7 | |
| SCHEMBL744630 | 0.82 | LMNA (0.49) | ACHEHPGDRAB9ATSHRKMT2A | |
| SCHEMBL16825022 | 0.82 | L3MBTL3 (0.79) | ACHEKMT2AL3MBTL3HRH3MEN1 | |
| SCHEMBL28292871 | 0.82 | EPHX1 (0.51) | ACHECA12CA1CA2CA7 | |
| SCHEMBL7424158 | 0.81 | MAPT (0.67) | ACHEHPGDALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2321965 | 0.81 | ACHE (0.67) | ACHECA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | claimed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | claimed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | claimed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | claimed |
| EP-3218374-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | claimed |
| WO-2016077380-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | claimed |
| CN-108368083-B | Heteroaryl compounds and their use as therapeutic agents | 东亚首希控股股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218374-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077380-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| CN-103110635-A | Histamine H3 receptor antagonist | NOVO NORDISK AS | 2013-05-22 | — | — | CN | disclosed |
| WO-2009150144-A1 | NEW GPR119MODULATORS | INOVACIA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| CN-101218206-A | Histamine H3 receptor antagonists | NOVO NORDISK AS (DK) | 2008-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | ACHE 2568/4885CA12 2309/4885CA1 1499/4885 |
| US-10150767-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | ACHE 2568/4885CA12 2309/4885CA1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.